Trial Profile
A Phase II Trial of PF-00299804 in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Sep 2016
Price :
$35
*
At a glance
- Drugs Dacomitinib (Primary)
- Indications Oesophageal cancer
- Focus Biomarker; Therapeutic Use
- 05 Sep 2016 Status changed from recruiting to completed.
- 24 Jul 2012 Actual initiation date (Jul 2012) added as reported by ClinicalTrials.gov.
- 01 Jul 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.